| Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. | Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI. Partnership ensures... ► Artikel lesen |
| UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Siemens Healthineers auf "Neutral" belassen. Wie die europäischen Investoren suchten auch jene aus den USA nach Signalen... ► Artikel lesen |
| ANALYSE-FLASH: Goldman senkt Ziel für Siemens Healthineers - 'Neutral' | NEW YORK (dpa-AFX Broker) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Siemens Healthineers von 52 auf 45 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Vor der Berichtssaison... ► Artikel lesen |
| BrightSpring Health Services, Inc.: BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita | LOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and... ► Artikel lesen |
| BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance | LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen |
| BrightSpring Health Services: Vor den Earnings: DIESE Healthcare-Aktie steht vor dem Breakout! | © Foto: Christian Charisius/dpaAktien aus dem Bereich des Gesundheitswesen sind in diesem Jahr gefragt. Dem US-Unternehmen BrightSpring Health Services gelingt es dabei, eine Nische zu bedienen. Das... ► Artikel lesen |
| Beta Bionics, Inc.: Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 | IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen |
| Beta Bionics, Inc.: Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics | IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary... ► Artikel lesen |
| Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen |